Neuroscientific Biopharmaceuticals (ASX: NSB) — Company Overview, News & Financial Data
Neuroscientific Biopharmaceuticals is a clinical-stage Australian biotechnology company advancing novel therapeutic technologies to treat immune-mediated inflammatory diseases and neurodegenerative disorders.
Neuroscientific Biopharmaceuticals
Neuroscientific Biopharmaceuticals is a clinical-stage Australian biotechnology company advancing novel therapeutic technologies to treat immune-mediated inflammatory diseases and neurodegenerative disorders. The company specializes in mesenchymal stem cell research through its proprietary stem cell platform, designed to enhance the safety, potency, and efficacy of stem cell therapies for complex autoimmune conditions such as refractory Crohn's disease. Additionally, Neuroscientific Biopharmaceuticals develops therapeutic drug candidates targeting neural tissue regeneration and neuroinflammation. Operating out of Perth, Western Australia, the company conducts research and clinical development aimed at addressing major unmet medical needs across global healthcare markets.
Snapshot
Operations
Products and/or services of Neuroscientific Biopharmaceuticals
- Cellular Therapy Platform: A patented cellular engineering system manufactured under Therapeutic Goods Administration license to produce mesenchymal stem cell treatments with heightened potency and anti-inflammatory properties for treating severe immune-mediated autoimmune disorders in clinical settings.
- Gastrointestinal Autoimmune Therapeutics: A clinical stage program utilizing modified mesenchymal stem cells in Phase 2 human trials to suppress chronic inflammation, repair intestinal mucosa, and restore tissue homeostasis in patients diagnosed with refractory Crohn's disease.
- Neuroprotective Peptide Therapeutics: A lead synthetic peptide compound modeled on metallothionein protein designed to inhibit neuroinflammation, prevent cell apoptosis, and stimulate axonal regeneration in central nervous system disorders including neurodegenerative diseases and neurodegenerative ocular injuries.
- Mesenchymal Stem Cell R&D: Specialized biomedical research focused on isolating and culturing adult stem cells from biological tissues, evaluating immune modulating responses, and optimizing cellular mechanisms that facilitate targeted tissue repair across inflammatory clinical models.
- Ophthalmic Neurodegeneration Treatments: Preclinical and early-stage clinical drug programs developing targeted molecular candidates to protect retinal ganglion cells, preserve optic nerve function, and prevent vision loss associated with glaucoma and optic neuritis diseases.
- GMP Contract Manufacturing Operations: Quality controlled biological manufacturing processes operating under regulatory compliance standards to prepare clinical trial batches, maintain cell line stability, and validate standardized scalable manufacturing protocols for cellular therapeutic products.
Neuroscientific Biopharmaceuticals executive team
- Mr. Nathan SmithChief Executive Officer
- Dr. Marian SturmChief Scientific Officer
- Dr. Catherine ColeChief Medical Officer
- Mr. Christopher Bryan James Achurch B.Com., C.A.Company Secretary